Shares of Sunesis Pharmaceuticals Inc. (NASDAQ: SNSS), a biopharmaceutical company engaged in the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers, surged in trading today after the company announced that it will implement a one-time, 225-patient sample size increase in its Phase 3 VALOR trial.
[...]
Recent Comments